Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

Trump and Xi Take AI to a Washington Summit Where One Side Defines Safety as Protecting Humanity and the Other as Protecting the Party

by Team Lumida
18 hours ago
OpenAI Discloses ‘Concerning’ Behavior in GPT-5.6 Sol; New Framework Launched as Safety Fears Delay IPO to 2027

Bessent says talks will cover open and closed weight models, putting China open-weight distribution strategy at the centre of the first AI dialogue since 2023.

Read more

SoftBank’s $50B SB Energy IPO Data Centre Gamble Pressured by OpenAI’s Delayed IPO; Nvidia Guarantees $105B for Ohio Campus

by Team Lumida
1 day ago
SoftBank’s $50B SB Energy IPO Data Centre Gamble Pressured by OpenAI’s Delayed IPO; Nvidia Guarantees $105B for Ohio Campus

OpenAI's delayed listing threatens SB Energy IPO timing; Son's $60B OpenAI bet interlinked with data centre strategy; SB Energy needs $170B capex, has zero operational facilities.

Read more

OpenAI Breached by Researchers Using Anthropic Tools; Anthropic Discloses 26% of R&D Led by AI in Recursive Self-Improvement Push

by Team Lumida
1 day ago
OpenAI Breached by Researchers Using Anthropic Tools; Anthropic Discloses 26% of R&D Led by AI in Recursive Self-Improvement Push

Hacktron AI researchers hacked OpenAI ChatGPT account via community forum flaw; received $6,500 bounty. Anthropic reveals Claude directs 26% of research, up from 1% in March.

Read more

Medical AI Has a ‘Proof Problem’: Only 2.4% of FDA-Approved Devices Backed by Trial Data; Nvidia, Microsoft, Google Face Regulatory Headwinds

by Team Lumida
1 day ago
Medical AI Has a ‘Proof Problem’: Only 2.4% of FDA-Approved Devices Backed by Trial Data; Nvidia, Microsoft, Google Face Regulatory Headwinds

Developers focus on statistical accuracy, not patient outcomes; 258 AI devices approved in 2025 without clinical trials; validation gaps could delay healthcare AI revenue for chip/software makers.

Read more

Nvidia Put $2 Billion Into Brookfield $10 Billion AI Infrastructure Fund, Anchoring a Fifth of the Vehicle

by Team Lumida
2 days ago
Nvidia Put $2 Billion Into Brookfield $10 Billion AI Infrastructure Fund, Anchoring a Fifth of the Vehicle

Investor documents reveal the size of Nvidia anchor stake in Brookfield AI infrastructure fund, which finances the power and compute its own chips require.

Read more

Zipline Drone Delivery Startup Raises $1B at $20 Billion Valuation; Nearly Triples Valuation From $7.6B Earlier This Year

by Team Lumida
2 days ago
Zipline Drone Delivery Startup Raises $1B at $20 Billion Valuation; Nearly Triples Valuation From $7.6B Earlier This Year

Paradigm to lead funding; Tiger Global participating; Zipline serves Chipotle, Walmart, Uber with 30-minute drone food delivery across 140M+ miles.

Read more

Chinese AI Models Generate Only 10% of OpenAI/Anthropic Revenue; Valuation Multiples Appear ‘Exorbitant’ for DeepSeek, Moonshot

by Team Lumida
2 days ago
Chinese AI Models Generate Only 10% of OpenAI/Anthropic Revenue; Valuation Multiples Appear ‘Exorbitant’ for DeepSeek, Moonshot

Rhodium Group analysis: DeepSeek $500M ARR, Moonshot $1B, Z.ai $1.8B vs OpenAI $40B, Anthropic $65B; Chinese startups at 50x-163x valuation ratios.

Read more

Brain-Computer Interface Startups Attract $1B+ 2026 Funding; Neuralink Leads $1.3B Raises as BCIs Converge With Prosthetics

by Team Lumida
2 days ago
Brain-Computer Interface Startups Attract $1B+ 2026 Funding; Neuralink Leads $1.3B Raises as BCIs Converge With Prosthetics

BCIs raised $1bn in 2026 vs $1.56bn in prior 4 years combined; Musk's Neuralink dominates; China designates BCIs strategic sector with state backing.

Read more

Google DeepMind Spinout Emulate Nears $4B Valuation After One Month; World Models Threaten $4.8T Gaming Industry

by Team Lumida
2 days ago
Google DeepMind Spinout Emulate Nears $4B Valuation After One Month; World Models Threaten $4.8T Gaming Industry

Former Google DeepMind researchers raise $700M for Emulate; Genie technology wiped billions from Take-Two, Roblox, Unity valuations; third UK neo-lab to exit Google.

Read more

OpenAI Discloses ‘Concerning’ Behavior in GPT-5.6 Sol; New Framework Launched as Safety Fears Delay IPO to 2027

by Team Lumida
2 days ago
OpenAI Discloses ‘Concerning’ Behavior in GPT-5.6 Sol; New Framework Launched as Safety Fears Delay IPO to 2027

OpenAI reveals 6 incidents of model misbehavior including constraint-ignoring, data fabrication, and deception; CEO Altman delays IPO as Anthropic expected public this year.

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

black and white star logo

SEC, Winklevoss’ Gemini to Resolve Crypto Lending Lawsuit

September 16, 2025
Mt. Fuji landamrk

Japan’s $62 Billion Gamble: Can It Save the Yen?

May 31, 2024
Private Credit Hits a Wall: Record Redemptions, Slowing Inflows, and Rising Alarm

Private Credit Hits a Wall: Record Redemptions, Slowing Inflows, and Rising Alarm

March 27, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018